Induced pluripotent stem cells are important research tools, but making and sharing them is far from easy. IMI’s EBiSC project has created a research infrastructure offering scientists a range of cell lines plus relevant advice and guidance.
The Innovative Medicines Initiative is a catalyst, and our research has been a launch pad for vital research infrastructures that will drive innovation long after projects have finished, writes IMI director Pierre Meulien.
IMI Associated Partner the TB Alliance values the way IMI brings together the main players, makes available resources, and creates a platform for collaboration with the industry, academia and the public sector.
Respiratory syncytial virus (RSV) still claims millions of mostly infant victims every year. IMI’s RESCEU project has put together the most comprehensive cache of evidence to date on the true burden of the disease.
As COVID-19 shows, older people are particularly vulnerable to infectious diseases. IMI’s VITAL project is studying vaccines and immunity in older adults, to figure out the best strategies to keep people healthier for longer.